- Home
- IPHA vs PLBY Comparison
IPHA vs PLBY Comparison
Compare IPHA & PLBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- PLBY
- Stock Information
- Founded
- IPHA 1999
- PLBY 1953
- Country
- IPHA France
- PLBY United States
- Employees
- IPHA N/A
- PLBY N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- PLBY Recreational Games/Products/Toys
- Sector
- IPHA Health Care
- PLBY Consumer Discretionary
- Exchange
- IPHA Nasdaq
- PLBY Nasdaq
- Market Cap
- IPHA 160.1M
- PLBY 174.3M
- IPO Year
- IPHA 2019
- PLBY N/A
- Fundamental
- Price
- IPHA $2.24
- PLBY $1.83
- Analyst Decision
- IPHA Strong Buy
- PLBY Buy
- Analyst Count
- IPHA 1
- PLBY 2
- Target Price
- IPHA $11.50
- PLBY $2.35
- AVG Volume (30 Days)
- IPHA 650.0K
- PLBY 940.9K
- Earning Date
- IPHA 03-20-2025
- PLBY 03-26-2025
- Dividend Yield
- IPHA N/A
- PLBY N/A
- EPS Growth
- IPHA N/A
- PLBY N/A
- EPS
- IPHA N/A
- PLBY N/A
- Revenue
- IPHA $36,202,722.00
- PLBY $124,761,000.00
- Revenue This Year
- IPHA N/A
- PLBY N/A
- Revenue Next Year
- IPHA $93.37
- PLBY $9.78
- P/E Ratio
- IPHA N/A
- PLBY N/A
- Revenue Growth
- IPHA N/A
- PLBY 30.09
- 52 Week Low
- IPHA $1.29
- PLBY $0.52
- 52 Week High
- IPHA $3.51
- PLBY $2.44
- Technical
- Relative Strength Index (RSI)
- IPHA 63.01
- PLBY 49.36
- Support Level
- IPHA $2.07
- PLBY $1.81
- Resistance Level
- IPHA $2.38
- PLBY $2.20
- Average True Range (ATR)
- IPHA 0.13
- PLBY 0.16
- MACD
- IPHA 0.04
- PLBY -0.03
- Stochastic Oscillator
- IPHA 78.79
- PLBY 13.95
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About PLBY PLBY Group Inc.
PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.